Home

Scott Akamine

CIK 1816720 · Chief Legal Officer · last filed 2026-04-20

Scott Akamine is a Chief Legal Officer who has filed 11 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for KLRA, was dated Apr 20, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

11

Lifetime Open-Market Net

-$1.37M

Filer Profile

Reported Address
C/O AEON BIOPHARMA, INC.
4040 MACARTHUR BLVD., SUITE 260
NEWPORT BEACH, CA 92660
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KLRA Chief Legal Officer — $13.94 — $0 1 2026-04-20
Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Chief Legal Officer 7,237 $44.96 $325.4K -$1.37M 6 2024-01-23
Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted Chief Legal Officer — $18.07 — $0 1 2021-06-03

Recent Filings

11 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-20 KLRA Grant (A) — $0 EDGAR
2024-08-05 — Disp (D) −7,527 $0
2024-01-23 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
2023-12-21 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed +6,724 -$292.9K EDGAR
2023-12-07 — Notice (144) −10,000 -$413.7K EDGAR
2023-12-07 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed — -$445.7K EDGAR
2023-12-05 — Notice (144) −7,500 -$262.5K EDGAR
2023-02-08 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
2022-08-09 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Mixed — -$268.3K EDGAR
2022-02-11 Cerevel Therapeutics Holdings, Inc. (CERE) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 11
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.